Want to see AU:EYE full AI Analyst Report?
EYE Stock Chart & Stats
AU$0.13
-AU$0.01(-5.26%)
At close: 4:00 PM EST
AU$0.13
-AU$0.01(-5.26%)
Day’s Range― - ―
52-Week RangeAU$0.10 - AU$0.21
Previous CloseN/A
Volume155.74K
Average Volume (3M)204.72K
Market Cap
AU$32.76M
Enterprise ValueAU$35.08M
Total Cash (Recent Filing)AU$2.62M
Total Debt (Recent Filing)AU$4.94M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding284,875,270
10 Day Avg. Volume176,528
30 Day Avg. Volume204,722
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)1.43
Price to Sales (P/S)0.93
P/FCF Ratio-4.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$42.45M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent top-line growth demonstrates rising customer adoption or market penetration in its product lines. Sustained revenue expansion provides scope to leverage fixed costs, supports investment in R&D or commercialization, and underpins a realistic path toward long-term profitability if margins stabilize.
Low LeverageA low debt load gives the company financial flexibility over a multi-month horizon: it reduces refinancing risk, lowers fixed financial costs, and preserves capacity to fund operations, clinical trials or strategic initiatives without immediate external dilution or distress financing.
Medical Devices ExposureOperating in the medical devices sector provides structural demand and regulatory-driven barriers to entry. This industry exposure supports durable revenue opportunities from clinical adoption cycles and potential recurring or upgrade-driven sales, benefiting long-term growth potential.
Bears Say
Margin DeteriorationA sharp decline in gross margin signals rising costs or pricing pressure that materially weakens unit economics. Persistently compressed margins reduce operating leverage, limit reinvestment capacity, and make achieving sustainable profitability harder without structural cost or pricing improvements.
Negative Cash GenerationOngoing negative operating and free cash flows indicate the business is not generating cash from core operations, forcing reliance on financing or equity raises. This undermines long-term self-funding, increases dilution risk, and constrains capital allocation for growth or R&D absent a clear cash turnaround.
Negative Return On EquityA negative ROE reflects capital destruction and weak returns on invested equity, signaling that existing assets and investments are not translating into shareholder value. Without a credible profitability recovery, continued negative ROE hampers ability to attract long-term capital and sustain growth.
Nova Eye Medical News
EYE FAQ
What was Nova Eye Medical’s price range in the past 12 months?
Nova Eye Medical lowest share price was AU$0.10 and its highest was AU$0.20 in the past 12 months.
What is Nova Eye Medical’s market cap?
Nova Eye Medical’s market cap is AU$32.76M.
When is Nova Eye Medical’s upcoming earnings report date?
Nova Eye Medical’s upcoming earnings report date is Aug 26, 2026 which is in 40 days.
How were Nova Eye Medical’s earnings last quarter?
Nova Eye Medical released its earnings results on Feb 25, 2026. The company reported -AU$0.012 earnings per share for the quarter, missing the consensus estimate of -AU$0.005 by -AU$0.007.
Is Nova Eye Medical overvalued?
According to Wall Street analysts Nova Eye Medical’s price is currently Overvalued.
Does Nova Eye Medical pay dividends?
Nova Eye Medical pays a Weekly dividend of AU$0.414 which represents an annual dividend yield of N/A. See more information on Nova Eye Medical dividends here
What is Nova Eye Medical’s EPS estimate?
Nova Eye Medical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nova Eye Medical have?
Nova Eye Medical has 284,875,270 shares outstanding.
What happened to Nova Eye Medical’s price movement after its last earnings report?
Nova Eye Medical reported an EPS of -AU$0.012 in its last earnings report, missing expectations of -AU$0.005. Following the earnings report the stock price went down -3.125%.
Which hedge fund is a major shareholder of Nova Eye Medical?
Currently, no hedge funds are holding shares in AU:EYE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nova Eye Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-40.41%
Trailing 12-Months
Asset Growth
-0.64%
Trailing 12-Months
Company Description
Nova Eye Medical
Nova Eye Medical Limited specializes in the creation, advancement, distribution, marketing, sale, and servicing of surgical equipment dedicated to treating glaucoma. Its diverse product line features iTrack, a surgical system engineered to decrease intraocular pressure (IOP) in adult patients with open-angle glaucoma, and iTrack Advance, an innovative system promoting natural ocular fluid drainage. Furthermore, the company provides Molteno3, a glaucoma drainage device for individuals suffering from severe or intricate forms of the condition, alongside 2RT, a proprietary laser technology employed to address early to intermediate stages of age-related macular degeneration. With a presence spanning Australia, the United States, Europe, the Asia Pacific, and other international markets, the company, originally established in 1985 as Ellex Medical Lasers Limited, officially became Nova Eye Medical Limited in July 2020. Its corporate headquarters are situated in Kent Town, Australia.
Technical Analysis
Cochlear
―
Compumedics Limited
―
Somnomed Limited
―
EMvision Medical Devices Ltd.
―
Control Bionics Ltd.
―